This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Stephen A. Cullinan, MD
Peoria, III

Charles G. Moertel, MD
Rochester, Minn

JAMA. 1986;255(3):322-323.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply—

We are very pleased that Drs Haller and Schein agree that the literature should not encourage the physician to accept FAM as established therapy for pancreatic cancer. Our data unequivocally support that conclusion, as does the randomized study led by Dr Schein that showed only a trivial 13% response rate and no survival advantage whatsoever when FAM was compared with a number of completely inactive drugs.¹ Since Dr Schein and his Georgetown group had stimulated the widespread use of FAM for pancreatic cancer, based on a claim of high response rates and responders living longer than nonresponders, we consider this to be a particularly courageous disclaimer and congratulate Dr Schein. We hope that now the book is closed on this issue and that FAM will no longer be promoted or used for advanced carcinoma of the pancreas.

We are perplexed that Drs Haller and Schein, and Dr . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?